PFE
Pfizer Inc.
Health Care / Pharmaceuticals / New York, NY
AnalystScope signal
Buy
Scheduled quote
$25
Base fair value
$28
Bear / base / bull
$21 / $28 / $34
Upside / downside
+12.0 upside
Confidence
Medium
Research updated Jun 13, 2026
Daily scheduled refresh as of Aug 1, 2026, 6:05 AM UTC. Fresh through Aug 2, 2026, 6:05 AM UTC.
Informational research only. Not personalized investment advice.
Model vs published view
Current model signal differs from the latest published analyst rating.
Investment summary
Current view and thesis
Pfizer adds a high-search health-care name, but the first view remains restrained because low multiples alone do not resolve leverage and growth-quality questions.
Fair value $28 vs. current $25 (+12.0 upside). Current base fair value is $28 versus $25, implying +12.0 upside.
Key drivers
Portfolio stabilization after pandemic-era revenue normalization is the core driver.
Cost actions and mix recovery can support margin repair.
Pipeline and acquisition integration determine the medium-term growth bridge.
Key risks
Revenue reset could last longer than the current base case assumes.
Debt and acquisition integration risk may keep valuation support muted.
Pipeline misses would make the low-multiple case less compelling.
What would change the view
Clear evidence of non-pandemic portfolio growth would improve the setup.
Debt reduction and stronger free cash flow would raise confidence.
Further revenue weakness or integration issues would keep the rating constrained.
Valuation
Price, range, and method support
Base case $28 / +12.0 upside / medium confidence
Price vs fair value
+12.0%
Model-implied return
Scheduled quote
$25
Fair value
$28
Valuation method stack
Weighted fair value $28
Published method weights
DCF (Base)
$29 | 45%
NTM P/E Multiple
$28 | 35%
EV/EBITDA Cross-check
$27 | 20%
| Case / method | Value | Weight / support |
|---|---|---|
| DCF (Base) | $29 | 45% |
| NTM P/E Multiple | $28 | 35% |
| EV/EBITDA Cross-check | $27 | 20% |
| Bear case | $21 | Mixed |
| Base case | $28 | Mixed |
| Bull case | $34 | Mixed |
Fundamental analysis
Reported evidence and normalized model base
Normalized annual basis: FY2025
Normalized figures are AnalystScope's annual valuation model base.
| Normalized metric | Latest value | Growth / margin context |
|---|---|---|
| Revenue | $62.0B | -2.5% YoY |
| Operating income | $13.6B | 21.9% margin |
| Net income | $8.7B | EPS proxy $1.53 |
| Free cash flow | $7.0B | 11.3% margin |
| EBITDA | $17.4B | 28.1% margin |
| Net cash / (debt) | -$48.0B | -77.4% of revenue |
| Metric | Reported | AnalystScope normalized | Basis note |
|---|---|---|---|
| Revenue (TTM) | $62.6B | $62.0B | Model revenue smooths the post-pandemic portfolio reset and avoids assuming a sharp immediate rebound. |
| Operating Margin | Unavailable | 21.9% | Margin input reflects cost actions and mix recovery but keeps pharma reinvestment needs visible. |
| FCF (TTM) | $9.1B | $7.0B | FCF input normalizes working-capital and integration timing after portfolio moves. |
| Net Cash / (Debt) | ($62.7B) | ($48.0B) | Balance-sheet treatment keeps leverage central to the rating rather than focusing only on low multiples. |
Fundamental snapshot
FY2025
Normalized annual model base
Revenue
-2.5% YoY
$62.0B
Op. margin
+0.9% pts
21.9%
FCF margin
+0.3% pts
11.3%
Revenue + margin trend
Annual normalized model-base history.
Revenue
Operating margin
AnalystScope annual model-base statements in USD across FY2023 | FY2024 | FY2025.
Income statement
| Line item | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Revenue | $58.5B | $63.6B | $62.0B |
| Gross Profit | $36.9B | $40.7B | $39.8B |
| Operating Income | $10.5B | $13.4B | $13.6B |
| EBITDA | $14.0B | $17.3B | $17.4B |
| Net Income | $4.1B | $7.6B | $8.7B |
Balance sheet
| Line item | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Cash & Investments | $12.0B | $12.5B | $13.0B |
| Total Debt | $62.0B | $61.5B | $61.0B |
| Net Cash / (Debt) | ($50.0B) | ($49.0B) | ($48.0B) |
| Total Assets | $226.0B | $229.0B | $231.0B |
| Total Liabilities | $131.0B | $133.0B | $134.0B |
| Shareholders' Equity | $95.0B | $96.0B | $97.0B |
Cash flow
| Line item | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Operating Cash Flow | $8.5B | $9.5B | $9.5B |
| Depreciation & Amortization | $3.5B | $3.9B | $3.8B |
| Capital Expenditures | ($2.3B) | ($2.5B) | ($2.5B) |
| Free Cash Flow | $6.2B | $7.0B | $7.0B |
Model assumptions
Base-case inputs and sensitivity
Published AnalystScope assumptions; private edits do not change this base case.
Revenue CAGR (5Y)
2.5%
+/- 1.0% => +/-$1/sh
Why this level: This is AnalystScope's base-case growth assumption, not a guarantee. It sits below the latest FY model-base revenue pace (2025.0%), so the model does not extend current strength too far into the outer years. Current company context: Pipeline and acquisition integration determine the medium-term growth bridge.
Terminal Growth
1.8%
+/- 0.5% => +/-$1/sh
Why this level: This is AnalystScope's mature long-run growth assumption, not a perpetual hypergrowth claim. At 1.8%, it sits well below the 2.5% five-year revenue CAGR, so the model steps down from the explicit forecast period to a steadier long-run pace. For Pfizer Inc., that means a durable franchise can keep compounding after year five without assuming today's faster growth profile lasts indefinitely.
WACC
8.4%
+/- 0.5% => -$2/sh
Why this level: This is AnalystScope's base-case cost-of-capital judgment, not a precise CAPM output. It reflects the current rates backdrop, equity risk premium, and the company's balance-sheet posture. Leverage and portfolio-reset execution remain central constraints
Operating Margin (Year 5)
23.0%
+/- 100 bps => +/-$1/sh
Why this level: This is AnalystScope's base-case margin view, not a promise of straight-line expansion. It keeps year-five margins close to today's model-base operating margin (21.9%), which implies the current margin structure is broadly durable. Margin input reflects cost actions and mix recovery but keeps pharma reinvestment needs visible.
Sensitivity drivers
Revenue CAGR (5Y)
2.5%
+/- 1.0% => +/-$1/sh
Terminal Growth
1.8%
+/- 0.5% => +/-$1/sh
WACC
8.4%
+/- 0.5% => -$2/sh
Operating Margin (Year 5)
23.0%
+/- 100 bps => +/-$1/sh
Confidence
Medium
Method outputs are tightly grouped at +7.1% dispersion.
Why the model view could be wrong
Revenue reset could last longer than the current base case assumes.
Debt and acquisition integration risk may keep valuation support muted.
Pipeline misses would make the low-multiple case less compelling.
Private analysis
Test your own assumptions in Scenario Builder
Private scenarios remain separate from AnalystScope's published base case.
Private workspace
Scenario Builder
Private scenario sandbox
This is a private modelling layer, not the public AnalystScope base case or printable snapshot. It keeps the public base case as the anchor, applies bounded changes to the four core valuation inputs, and updates your scenario fair-value estimate immediately.
Saved scenarios currently stay local to this browser for PFE. Base-case rationale remains in the public assumptions section above. Your scenario output reprices the published valuation methods from projected operating anchors when those anchors are available, while keeping market-multiple and capital-structure assumptions anchored to the AnalystScope framework.
Editable assumptions
Adjust your scenario inputs within the displayed plausible range for this company. The workbench stays anchored to the public AnalystScope base case.
This is a bounded scenario tool, not a free-form spreadsheet. Values outside the displayed range snap back to the nearest allowed value when you leave the field.
Matches the published AnalystScope base case.
Revenue CAGR (5Y)
Public AnalystScope base case: 2.5% | +/- 1.0% => +/-$1/sh
Allowed range: 0.0% to 8.5%
Terminal Growth
Public AnalystScope base case: 1.8% | +/- 0.5% => +/-$1/sh
Allowed range: 1.0% to 3.3%
WACC
Public AnalystScope base case: 8.4% | +/- 0.5% => -$2/sh
Allowed range: 6.4% to 10.4%
Operating Margin (Year 5)
Public AnalystScope base case: 23.0% | +/- 100 bps => +/-$1/sh
Allowed range: 15.0% to 31.0%
Saved private scenarios
Save up to 5 named scenarios for PFE. These are your scenarios: they never overwrite the public AnalystScope base case and remain clearly separate from public research.
Checking private workspace session...
Private scenario note
Keep a short thesis, main risk, or why this case differs from the published base case.
0 / 280
Notes stay local to this browser unless you sign in to the private workspace, and they never appear as published AnalystScope research.
No private scenarios saved yet. Make a change to the published base case, then save a named scenario here.
Published base case
Fair value
$28
Upside / Downside
+12.0 upside
Model signal
Buy
Published base-case output
Scenario output reprices the published DCF and multiple methods from projected year-5 revenue, margin, free cash flow, EBITDA, and EPS anchors. Market multiples and capital structure stay anchored to the published base framework.
Fair value
$28
$0/sh vs published base case
Upside / Downside
+12.0 upside
+0.0 pts vs published base case
Model signal
Buy
Unchanged versus the published base case.
Method movement inside the scenario
This breakdown shows what moved inside the published valuation framework when you edit the scenario. The published AnalystScope base case stays anchored, and any method without a clean projected anchor remains pinned to that framework.
Method rows below reflect the current edited scenario state, not just the saved scenario snapshots.
Influence tags are directional rather than exact attribution. They estimate which edited input is moving each method most by reverting one assumption at a time while the other edited inputs stay in place.
| Method | Published base | Edited scenario | Delta | How it moved / main drivers |
|---|---|---|---|---|
DCF (Base) DCF-style | 45% weight | $29 | $29 | $0/sh | Base-aligned This method is supported by the model-native bridge and currently stays aligned with the published base case. Edited inputs are largely offsetting each other, so this row stays close to the published base case. |
NTM P/E Multiple P/E-style | 35% weight | $28 | $28 | $0/sh | Base-aligned This method is supported by the model-native bridge and currently stays aligned with the published base case. Edited inputs are largely offsetting each other, so this row stays close to the published base case. |
EV/EBITDA Cross-check EV-based multiple | 20% weight | $27 | $27 | $0/sh | Base-aligned This method is supported by the model-native bridge and currently stays aligned with the published base case. Edited inputs are largely offsetting each other, so this row stays close to the published base case. |
Weighted fair value Published framework result | Published framework result | $28 | $28 | +$0/sh | Moved Combines the repriced method outputs using the published AnalystScope weights. No single edited assumption is dominating this move in a material way. |
Published base case vs private scenarios
Compare the published AnalystScope base case against your saved private scenarios in one view. Saved scenarios remain local to this browser, and the table below reflects saved snapshots rather than any unsaved edits currently sitting in the editor.
Fair-value comparisons use the same workbench recalculation path as the editor above.
Published base case stays pinned as the anchor row.
| Scenario | Revenue CAGR (5Y) | Terminal Growth | WACC | Op. Margin (Y5) | Fair Value | Upside / Downside | Model Signal | Delta vs Base | Action |
|---|---|---|---|---|---|---|---|---|---|
AnalystScope base case PublishedOfficial AnalystScope anchor row. | 2.5% | 1.8% | 8.4% | 23.0% | $28 | +12.0 upside | Buy | Published anchor |
Supporting research
Quality, normalization, and monitoring evidence
Annual model base: FY2023 | FY2024 | FY2025
Thesis scorecard
Growth
WeakThe revenue base is still resetting after pandemic-era demand.
Profitability
ModerateMargins can improve, but mix and reinvestment remain important.
Balance sheet
WeakDebt is a real constraint for the current model.
Valuation
ModerateThe multiple is low, but the model does not treat that as enough on its own.
Execution / Resilience
ModeratePipeline and integration execution need evidence.
Current source status
Quote: Daily scheduled refresh as of Aug 1, 2026, 6:05 AM UTC. Fresh through Aug 2, 2026, 6:05 AM UTC.
Reported fundamentals: Fundamentals refreshed 1 Aug 2026, 16:00 UTC. Fresh through 2 Aug 2026, 04:00 UTC.
Latest filing: 4 filed Jul 16, 2026 | Reporting period Jul 15, 2026. Filing refreshed Aug 1, 2026, 4:26 PM UTC. Fresh through Aug 2, 2026, 4:26 AM UTC.
Annual model-base income-statement, cash-flow, and balance-sheet metrics, plus cross-statement quality relationships with compact prior-FY direction cues, derived from the curated statement backbone.
Basis: FY2023 | FY2024 | FY2025. Live reported fundamentals remain available in the reconciliation section.
Operating and cash-flow trends
Revenue growth (1Y)
-2.5%
Gross margin
64.2%
Operating margin
21.9%
Operating margin change vs prior FY
+0.9 pts
EBITDA margin
28.1%
EBITDA margin change vs prior FY
+0.9 pts
Operating income growth (1Y)
+1.5%
Net margin
14.0%
FCF margin
11.3%
FCF margin change vs prior FY
+0.3 pts
FCF growth (1Y)
+0.0%
Balance sheet quality
Cash & investments
$13.0B
Total debt
$61.0B
Net cash / (debt)
Net debt $48.0B
Net cash / (debt) as % of revenue
Net debt 77.4% of revenue
Liabilities / assets
vs FY2024 (-0.1 pts)
58.0%
Cross-statement quality
Gross-to-operating spread
42.3 pts
Operating cash flow / net income
vs FY2024 (-0.2x)
1.1x
Operating cash flow / EBITDA
vs FY2024 (-0.0x)
0.5x
Free cash flow / net income
vs FY2024 (-0.1x)
0.8x
CapEx as % of revenue
vs FY2024 (+0.1 pts)
4.0%
CapEx as % of operating cash flow
vs FY2024 (+0.0 pts)
26.3%
CapEx / D&A
vs FY2024 (+0.0x)
0.7x
Cash & investments / total debt
vs FY2024 (+0.0x)
0.2x
Shareholders' equity as % of revenue
156.5%
Asset turnover
vs FY2024 (-0.0x)
0.3x
Compact model-base diagnostics for analyst triage, highlighting where the durable valuation base is diverging most clearly from the latest reported picture.
Adjustment focus
Large analyst adjustmentBalance sheet | Net Cash / (Debt) | +$14.7B / +23% of revenue
Revenue momentum
Weakening-2.5% latest 1Y growth
vs +8.7% prior 1Y
Operating margin trend
Stable21.9% latest margin
+87 bps vs prior FY
FCF margin trend
Stable11.3% latest FCF margin
+28 bps vs prior FY
Balance-sheet posture
StableNet debt 77.4% of revenue
vs Net debt 77.0% of revenue prior FY
How to read this
Reported = the latest company-reported figure. Model base = AnalystScope's comparable operating base used for valuation and thesis work. It may include standardization, conservative balance-sheet treatment, working-capital cleanup, and through-cycle adjustments when current reported numbers do not look durable.
This is an analyst model base, not a claim of perfect adjusted truth. Larger gaps can reflect deliberate cyclical or base-case adjustments, not just light accounting cleanup.
Why the model base differs
Pfizer is modeled as a low-multiple pharmaceutical reset story where leverage and evidence of portfolio stabilization matter as much as headline valuation.
Rows are sorted by largest comparable adjustment first.
| Metric | Model base | Live reported | Variance vs reported | Adjustment size | Why lower / higher? |
|---|---|---|---|---|---|
Net Cash / (Debt) | ($48.0B) FY2025 model base | ($62.7B) Live reported balance sheet | +$14.7B / +23% of revenue | Large analyst adjustment | Model base is less conservative than the live reported balance-sheet figure because the latest reported balance does not appear fully representative. It keeps leverage central to the rating rather than focusing only on low multiples. |
FCF (TTM) | $7.0B FY2025 model base | $9.1B Live reported TTM | -$2.1B / -23% | Large analyst adjustment | Model base is lower than live reported because cash generation is being smoothed for timing effects rather than taken at face value. It normalizes working-capital and integration timing after portfolio moves. |
Revenue (TTM) | $62.0B FY2025 model base | $62.6B Live reported TTM | -$600.0M / -1% | Close to reported | Model base is lower than live reported because the thesis does not carry the current revenue run-rate straight into the durable operating base. It smooths the post-pandemic portfolio reset and avoids assuming a sharp immediate rebound. |
Operating Margin | 21.9% FY2025 model base | Unavailable Live reported margin | Unavailable | Unavailable | AnalystScope keeps a separate model base when the latest reported figure is unavailable or not directly comparable. It reflects cost actions and mix recovery but keeps pharma reinvestment needs visible. |
Near-term catalysts
Portfolio-growth commentary and pipeline milestones remain key.
Cost-savings progress can affect margin confidence.
Free-cash-flow conversion and debt reduction are important model checks.
What we are watching
Whether core product growth is enough to offset mature and declining franchises.
How quickly leverage begins to move lower.
Whether cost actions improve margins without damaging the growth bridge.
| Date | Event | Published rating | Note |
|---|---|---|---|
| Jun 13, 2026 | New | Hold | Started coverage with a Hold view on low-multiple support versus leverage and growth-reset risk. |